Vimarsana
Biggest News Aggregation in the World

Page 35 - Accessed May News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed May. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed May Today - Breaking & Trending Today

VERA FILES FACT CHECK: Badoy repeats misleading claim on 2015 SC ruling - Vimarsana News

VERA FILES FACT CHECK: Badoy repeats misleading claim on 2015 SC ruling

This is at least the second time that Lorraine Badoy misled information about the 2015 Supreme Court ruling.

Fracture Risk Reduction Greater With Denosumab vs Alendronate, According to Real-World Data - Vimarsana News

Fracture Risk Reduction Greater With Denosumab vs Alendronate, According to Real-World Data

Prolia achieved greater reductions in fracture risk in postmenopausal women compared with oral alendronate, according to a real-world study.

New Research Supports Standardization of Reporting for Incidental Findings in Lung Cancer Screening - Vimarsana News

New Research Supports Standardization of Reporting for Incidental Findings in Lung Cancer Screening

Results showed standardized reporting was frequently used in low-dose computed tomography lung screening, with the majority of instances being considered reportable to the clinician and requiring follow-up.

First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis - Vimarsana News

First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study...

Johnson & Johnson : First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis - Vimarsana News

Johnson & Johnson : First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis

That cause chronic inflammation of the gastrointestinal tract.6 Prolonged inflammation results in damage to the GI tract.6 The exact cause of IBD is unknown but may be the result of the immune... | May 9, 2023